Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038019 | 0.80 | GAA (0.45) | IDO1MEN1GAAHPGDKMT2A | |
| SCHEMBL2259312 | 0.75 | KMT2A (0.36) | MEN1KMT2A | |
| SCHEMBL2492162 | 0.74 | OGA (0.40) | MEN1GAAHPGDKMT2AALDH1A1 | |
| SCHEMBL3149167 | 0.72 | MET (0.42) | — | |
| SCHEMBL21138127 | 0.70 | CCNC (0.45) | IDO1SLC22A12AAK1 | |
| SCHEMBL2498299 | 0.69 | AKR1C3 (0.40) | KMT2A | |
| SCHEMBL12985302 | 0.69 | MAPT (0.38) | — | |
| SCHEMBL10322728 | 0.69 | MAPT (0.38) | KMT2AALDH1A1 | |
| SCHEMBL4074821 | 0.69 | MAPT (0.39) | — | |
| SCHEMBL20935446 | 0.69 | IDO1 (0.41) | IDO1CYP2C9CYP2C19SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012961-B2 | Tricyclic antibiotics | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| EP-2276766-A1 | TRICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009128019-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | OPRM1, UBE2D3, METTL3 | IDO1 450/4885MEN1 1111/4885GAA 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.